StreetInsider.com News Articles

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET)

BOCA RATON, Fla, Sept. 09, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced their attendance at the H.C. Wainwright 28^th Annual Global Investment Conference, taking place September 14-16 at the Lotte New York Palace Hotel in New York City.

David Moss, Founder and Chief Executive Officer, will be hosting one-on-one meetings with institutional investors on September 14 - 16 and will be presenting on Monday, September

INmune Bio to Present at the H.C. Wainwright Global Investment Conference

Wed, 09 Sep 2026 08:00:00 -0400

The on-demand presentation will be available on September 11, 2026, at 7:00 A.M. (ET)

David Moss, Founder and Chief Executive Officer, will be hosting one-on-one meetings with institutional investors on September 14 - 16 and will be presenting on Monday, September

INmune Bio files for EMA orphan drug status for its RDEB cell therapy

Wed, 26 Aug 2026 07:02:02 -0400

INmune Bio Inc. (NASDAQ: INMB) has submitted two regulatory packages to the European Medicines Agency for its investigational cell therapy Ebstrocel™, according to a company statement.

The filings include an application for Orphan Drug Designation and a pre-Marketing Authorization Application Scientific Advice package for Ebstrocel™ in recessive dystrophic epidermolysis bullosa, a rare genetic disease marked by severe skin fragility and chronic wounds.

If the orphan designation is granted and maintained through approval, the therapy could receive 10 years of EU market exclusivity, along with regulatory incentives such as protocol assistance and fee reductions during development. INmune Bio already holds Orphan Drug Designation

INmune Bio files for EMA orphan drug status for its RDEB cell therapy

Wed, 26 Aug 2026 07:02:02 -0400

INmune Bio Inc. (NASDAQ: INMB) has submitted two regulatory packages to the European Medicines Agency for its investigational cell therapy Ebstrocel™, according to a company statement.

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Wed, 26 Aug 2026 07:00:00 -0400

Orphan Drug Designation application and pre-MAA Scientific Advice package submitted for Ebstrocel™ in RDEB
Filings support a planned EU MAA in Q1 2027; orphan designation, if granted and maintained through approval, may provide regulatory incentives and 10 years of market exclusivity

BOCA RATON, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) ("INmune Bio" or the "Company"), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted two regulatory packages to the European Medicines Agency (EMA) for Ebstrocel™: an application for Orphan Drug Designation and a Scientific

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Wed, 26 Aug 2026 07:00:00 -0400

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Wed, 26 Aug 2026 07:00:00 -0400

INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings

Wed, 26 Aug 2026 07:00:00 -0400

INmune Bio, Inc. (INMB) Tops Q2 EPS by 14c

Thu, 06 Aug 2026 17:38:05 -0400

INmune Bio, Inc. (NASDAQ: INMB) reported Q2 EPS of ($0.05), $0.14 better than the analyst estimate of ($0.19).

For earnings history and earnings-related data on INmune Bio, Inc. (INMB) click here.

Form 10-Q Inmune Bio, Inc. For: Jun 30

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883808.html

Form 10-Q Inmune Bio, Inc. For: Jun 30

Thu, 06 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260806/26883808.html

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

Thu, 06 Aug 2026 16:00:00 -0400

Company to Host Conference Call Today, August 6th, at 4:30pm ET

BOCA RATON, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced its financial results for the quarter ended June 30, 2026 and provided a business update.

“The second quarter and subsequent weeks were defined by execution across both of our late-stage platforms,” said David Moss, Chief Executive Officer of INmune Bio. “For Ebstrocel™, we secured MHRA alignment, PIP approval and commercial-ready manufacturing, materially reducing regulatory and operational risk

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

Thu, 06 Aug 2026 16:00:00 -0400

Company to Host Conference Call Today, August 6th, at 4:30pm ET

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

Thu, 06 Aug 2026 16:00:00 -0400

Company to Host Conference Call Today, August 6th, at 4:30pm ET

INmune Bio Inc. Announces Second Quarter 2026 Results and Highlights Regulatory, Manufacturing and Clinical Progress

Thu, 06 Aug 2026 16:00:00 -0400

Company to Host Conference Call Today, August 6th, at 4:30pm ET

Form 8-K Inmune Bio, Inc. For: Jul 31

Fri, 31 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26850653.html

Form 8-K Inmune Bio, Inc. For: Jul 31

Fri, 31 Jul 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26850653.html

INmune Bio receives $4.6M in R&D rebates from UK and Australia

Fri, 31 Jul 2026 07:00:48 -0400

INmune Bio Inc. (NASDAQ: INMB) announced it received a combined $4.6 million in research and development cash rebates from government programs in Australia and the United Kingdom, according to a press release.

The company received approximately $4.2 million from Australia on July 30, 2026, and approximately $0.4 million from the UK in June 2026. The rebates were generated through established government programs supporting qualifying research and development activity conducted in those countries, reflecting eligible expenditures related to clinical development, manufacturing, and regulatory activities.

INmune Bio said that after adjusting second-quarter operating cash flows to exclude the UK rebate received during that period,

INmune Bio Receives R&D Rebates of Approximately $4.6 Million